**Stockport CCG prescribing restriction lists**

The Stockport CCG Black and Grey Listing prevents prescribing of drugs deemed to be less suitable for prescribing due to safety, efficacy or of poor value for the NHS.

Any product can be nominated for considered for listing by NHS Stockport clinicians or CCG staff. Products added to the Do Not Prescribe list produced by the GMMMG Formulary Group will automatically be added. Product considered by GMMMG for the Do Not Prescribe or grey list at a GM level will be reviewed locally, in case there is a different position locally.

Name of product(s) to be considered: Evoke E-Cigarettes

Reason for product nomination (*attach additional evidence if necessary*)

* added to the GMMMG DNP List in May 2016. CCG follows GMMMG DNP list.

**Criteria for Inclusion on the Stockport CCG Black list**

*Select from the list below (There does not need to be agreement with all statements but all need to be considered when completing the form for submission to STAMP)*

1. There is a NHS Stockport Policy in place that would preclude the use of the drug/preparation routinely including listing as Do Not Prescribe by GMMMG
2. The drug has an absolute ‘not recommended’ position allocated by NTS from January 2011 as it has limited clinical effectiveness (and data is against placebo) or cost effectiveness data.
3. There is no instance where this drug/ preparation would be appropriate to use from a safety or efficacy point of view, over existing treatments. This may mean there are no further drug options for that patient group\* ( if this is not the case consider statement 10)
4. There are more appropriate evidence based alternative(s) available that means this drug/ preparation should not be prescribed in any situation\* or drug has a grey listing on the GMMMG DNP and Grey list.
5. The evidence base is so poor that it would not be an appropriate use of NHS resources to prescribe this drug/ preparation in any situation. This includes a lack of robust, published phase III RCTs, weak evidence, such as limited benefit in trials against placebo or opinion only\*
6. There is sufficient concern over safety that it is not appropriate for this drug to be prescribed\*
7. There is a DO NOT Do statement in a NICE guideline or a negative NICE Technology Appraisal not recommending its use. If NICE has not considered a drug then SMC and AWMSG decisions can be considered.
8. The drug is a ‘me too’ drug that doesn’t offer any additional proven benefit over the existing drug or other therapies
9. The drug is considered by the BNF Joint Formulary Committee to be less suitable for prescribing
10. STAMP considers that there is a only a narrow, defined place for use of the drug/ preparation*.(Such drugs will be grey listed to allow use within this defined situation)*

\* Whilst prescribers should think very carefully before prescribing or recommending any of the DNP products, there may be exceptional instances when the use of one of these products is necessary for a particular patient. A patient may be deemed exceptional if the patient has a clinical picture that is significantly different to the general population of patients with that condition and as a result of that difference the patient is likely to derive greater benefit from the intervention than might normally be expected for patients with that condition. Before prescribing clinicians should seek approval to prescribe from the CCG to ensure the CCG agrees the exceptionality and approves prescribing outside of the policy

Criteria for blacklisting 1 Date STAMP reviewed June 1st 2016

Review outcome

Approved for Black Listing Yes

Approved for Grey Listing No

Criteria for permissible grey list use: Not applicable

Outcome confirmed on behalf of STAMP (Chair of meeting)

Signed . Designation